Tipoline vs. semaglutide: Which is right for you?

With the development of medical weight loss drugs, GLP-1 receptor agonists have gradually become the mainstream choice for obese people. Among them, semaglutide is widely used due to its significant weight loss effect, while the more advanced GLP-1/GIP dual agonist telpolide has stood out in clinical research with its stronger weight loss ability.

Both medications are injectable weight-loss drugs and are both FDA- approved, but they differ significantly in their mechanisms of action, weight-loss speed, side effects, and suitable populations. This article will compare clinical data to help you scientifically determine which medication is more suitable for you.

 

1. Comparison of drug mechanisms of action: single agonist vs. dual agonist

Dimension	Telpoeptide	Smegglutide
Agonist type	GLP-1 + GIP dual agonist	GLP-1 single agonist
Target	Appetite center, pancreatic β cells, adipocytes	Appetite center, gastric emptying regulation
Mechanism characteristics	Suppresses appetite + promotes fat breakdown + improves insulin sensitivity	Suppresses appetite and delays gastric emptying
metabolic regulation capacity	Strong (can improve blood sugar and insulin resistance)	medium

📌 In summary , telpoeptide, through a dual agonist mechanism, not only more effectively suppresses appetite but also actively stimulates fat breakdown and optimizes metabolic state , resulting in a more comprehensive mechanism of action.

 

2. Weight Loss Results Comparison: Which is Faster? Which is More Stable?

SURMOUNT -1 study, 72 weeks.

•       Average weight loss was 22.5%.

•       More than 57% of people lost ≥20% of their weight.

•       The maximum weight loss can reach 27%.

Smegglutinin ( STEP-1 study, 68 weeks)

•       Average weight loss was 16.9%.

•       Approximately 36% of people experienced a weight loss of ≥20% .

•       The maximum weight loss is approximately 18%.

📌 In summary , under similar usage periods, telpolide exhibits significantly stronger and faster weight loss effects, making it more suitable for individuals with higher body weight .

 

3. Side effects and tolerability: Which drug is gentler?

Side effect types	Mounjaro (a type of peptide)	Smegglutinin ( Wegovy )
nausea	31%	44%
Vomit	18%	twenty four%
diarrhea	twenty one%	30%
constipate	14%	17%
fatigue	7%	10%

📌 In summary , telpolide, due to its GIP component, can neutralize some of the gastrointestinal irritation caused by GLP-1 , resulting in milder gastrointestinal discomfort in clinical manifestations. It is more tolerable than smegglutide and is more suitable for long-term use.

 

4. Comparison of target audiences: Which one is right for you?

Population characteristics	Recommended medication	Explanation of reasons
BMI ≥ 30 , need rapid and significant weight loss	Telpoeptide	Significant and rapid weight loss
BMI ≥27 , accompanied by metabolic problems such as diabetes and fatty liver.	Telpoeptide	It has a stronger ability to lower blood sugar and improve metabolism.
Sensitive to the side effects of injectable drugs	Telpoeptide	Better gastrointestinal tolerance
The goal is gentle weight loss with manageable side effects.	Smegglutide	Patients who can tolerate mild discomfort
With a limited budget, let's try GLP-1 drugs first.	Smegglutide	The market price is slightly lower than that of telpoeptide.

5. Telborpeptide vs. Smegglutinin: How to choose?

📌 Choosing telpolide is more suitable:

•       To lose more than 15% , especially for people with a BMI of 35 or higher.

•       Accompanied by health problems such as metabolic syndrome and prediabetes

•       People who want to use it long-term but have concerns about side effects and tolerance.

📌 Choosing Smegglutide is more suitable:

•       The goal is moderate weight loss ( 10%-15% ).

•       For those looking to try the GLP-1 entry-level version and considering the price.

💡 Conclusion : Telborpeptide is superior to Smegglutinin in both weight loss effect and tolerability, making it the most cost-effective weight loss injection currently available.